Over the past couple of years, the engineered biology market has seen fledgling companies rise to IPO smashing power players, as the demand for high-quality, engineered biomolecules and controllable therapeutics grows exponentially.
The therapeutic potential of novel synthetic units is huge, but challenges remain in demonstrating proof-of-concept, developing assays, functional characterization, manufacturing scale-up, and identifying therapeutic applications for commercial development.
Returning for the 2nd year, the Synthetic Biology-Based Therapies Summit is the industry-defining forum made exclusively for leaders in the synthetic and engineered biology space, focusing on the technical challenges that lie ahead in the path towards commercialization.
Learn from industry trailblazers at Arsenal Biosciences, bit.bio, MIT, Novome Bio, Strand Therapeutics, Synlogic and more, to support your efforts in developing safe and effective synthetic biology-based therapeutics.
The therapeutic potential of novel synthetic units is huge, but challenges remain in demonstrating proof-of-concept, developing assays, functional characterization, manufacturing scale-up, and identifying therapeutic applications for commercial development.
Returning for the 2nd year, the Synthetic Biology-Based Therapies Summit is the industry-defining forum made exclusively for leaders in the synthetic and engineered biology space, focusing on the technical challenges that lie ahead in the path towards commercialization.
Learn from industry trailblazers at Arsenal Biosciences, bit.bio, MIT, Novome Bio, Strand Therapeutics, Synlogic and more, to support your efforts in developing safe and effective synthetic biology-based therapeutics.
